Meghan J Mooradian

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Meghan J Mooradian

Sep 8, 2024, 16:13 | Insight

Tomas G. Neilan: Can large language models outperform ICD codes in detecting severe immune-related adverse events?

Tomas G. Neilan, Director of the Cardio-Oncology Program at Massachusetts General Hospital, shared on X:…

Apr 14, 2024, 07:51 | Insight

New Paper Alert! Defining Dermatologic Immune-Related Adverse Events: A Consensus-Driven Approach

Defining Dermatologic Immune-Related Adverse Events: A Consensus-Driven Approach Published in Journal for ImmunoTherapy of Cancer,…

All: 2 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023